News

Targeted Therapeutics for Cancer and Ophthalmology

Latest News

April 8, 2015
TRACON Pharmaceuticals Expands License Agreement and Signs Research Agreement with Case Western Reserve University

April 7, 2015
TRACON Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference

March 10, 2015
TRACON Pharmaceuticals Reports 2014 Year-End Financial Results and Recent Corporate Highlights

February 28, 2015
TRACON Pharmaceuticals Announces Positive Phase 1b Results for TRC105 in Combination With Inlyta(R) (axitinib) at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium

February 27, 2015
TRACON Pharmaceuticals Appoints Stephen Worland to Its Board of Directors

Febuary 19, 2015
TRACON Pharmaceuticals Announces Upcoming Presentation of Results From a Clinical Trial of TRC105 in Patients With Renal Cell Carcinoma at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium

January 29, 2015
TRACON Pharmaceuticals Announces Pricing of Initial Public Offering

January 9, 2015
TRACON Pharmaceuticals Announces Results from a Clinical Trial of TRC105 in Patients with Hepatocellular Carcinoma to be Presented at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium

December 1, 2014
TRACON Pharmaceuticals Initiates Randomized Phase 2 Clinical Trial of TRC105 in Patients with Renal Cell Carcinoma

September 24, 2014
TRACON Pharmaceuticals Announces Results from Clinical Trials of TRC105 in Patients with Ovarian Cancer to be Presented at the 2014 Annual Meeting of the European Society for Medical Oncology

September 22, 2014
TRACON Pharmaceuticals Completes $27 Million Financing and Expands Management Team and Board of Directors

September 4, 2014
TRACON Pharmaceuticals Initiates Phase 2 Clinical Trial of TRC105 in Patients with Soft Tissue Sarcoma

August 4, 2014
TRACON Pharmaceuticals Appoints William LaRue to its Board of Directors

March 4, 2014
Santen and TRACON Announce Agreement for the Development and Commercialization of TRC105 in Ophthalmology

February 3, 2014
TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105 in Patients with Advanced Soft Tissue Sarcomae

October 22, 2013
TRACON Pharmaceuticals Announces TRC105 Data Presented at the 2013 AACR‐NCI‐EORTC International Conference

September 23, 2013
TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105 in Patients with Metastatic Renal Cell Carcinoma

May 20, 2013
TRACON Pharmaceuticals Announces TRC105 Clinical Trials, Abstract Presentations at 2013 ASCO Annual Meeting

April 17, 2013
TRACON Pharmaceuticals Announces Publication of Mechanism of Action of TRC105, a Novel Anti‐Angiogenic Antibody

December 6, 2011
TRACON Pharmaceuticals announces appointment of Kenneth Galbraith as Chairman of the Board

April 20, 2011
TRACON Pharmaceuticals announces $22 million tranched investment led by JAFCO and Nextech to fund TRC105 Phase 2 development

October 25, 2010
TRACON Pharmaceuticals announces upcoming scientific presentations on clinical-stage cancer therapeutics TRC102 and TRC105

April 26, 2010
TRACON Announces Start of Phase 1/2 Trial of TRC105 Antibody Therapy for Prostate Cancer

April 13, 2010
Prostate Cancer Foundation Issues $4.5 Million in Grants to Support Innovation from Young Investigators

March 22, 2010
Formatech Donates Services to Formulate and Fill Tracon Pharmaceuticals’ TRC102 Compound under Its “Fillanthropy™ Program”

November 9, 2009
TRACON Pharmaceuticals Announces Upcoming Presentation of Clinical Data on TRC102, a Selective Inhibitor of DNA Base Excision Repair and Chemotherapy Resistance

October 19, 2009
TRACON announces CRADA with NCI to study TRC105 in prostate cancer

May 26, 2009
TRACON Pharmaceuticals’ small molecule TRC102 and antibody TRC105 to be presented at ASCO 2009

February 17, 2009
Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009

October 22, 2008
Tracon Pharmaceuticals, Inc. to Present at the BIOCOM Investor Conference

October 21, 2008
Tracon Pharmaceuticals Appoints Bryan Leigh, M.D. as Chief Medical Officer

June 18, 2008
TRACON Pharmaceuticals Doses the First Patient in a Phase 1 Clinical Trial with Oral TRC102, an Inhibitor of Chemotherapy Resistance, in Combination with Alimta®

February 25, 2008
First Patient Treated with Novel “First-in-Class” Anti-Cancer Drug

January 9, 2008
TRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial with TRC105, a Human Chimeric Antibody

November 2, 2007
TRACON Pharmaceuticals to Present at the Rodman & Renshaw 9th Annual Healthcare Conference

March 16, 2007
Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment

November 3, 2006
Tracon Pharmaceuticals, Inc. announces presentation at Rodman & Renshaw 8th Annual Healthcare Conference

October 12, 2006
Case Licenses Methoxyamine to Tracon

August 2, 2006
Tracon Pharmaceuticals appoints Charles P.Theuer, M.D., Ph.D as President and Chief Executive Officer

March 14, 2006
TRACON Pharmaceuticals assembles industry-leading management team to support development of targeted cancer therapy pipeline

April 16, 2005
Lexington Pharmaceuticals changes name to TRACON Pharmaceuticals, Inc. Lexington Pharmaceuticals announced that it has changed its name to TRACON Pharmaceuticals, Inc., and has moved the company from New York, New York to San Diego, California.

April 1, 2005
Lexington Pharmaceuticals names Bert Liang, MD MBA as President and CEO. Dr. Liang was formerly Vice President of New Ventures, at Biogen Idec.